Q1 FY27: Strong Growth, Key Acquisition, and Shareholder Returns
Jagsonpal Pharmaceuticals Limited · JAGSNPHARM · NSE ·
<b>Strong Q1 FY27 Performance:</b> Reported a 22% YoY increase in Profit After Tax (PAT) to ₹13 crores and a ~9% rise in revenue to ₹82 crores. EBITDA margins expanded significantly to over 23%. <b>Acquires Aequitas Healthcare:</b> Completed the acquisition of an 85% stake for ₹2…